Restricted Research - Award List, Note/Discussion Page
Fiscal Year: 2023
1798 The University of Texas at El Paso (143686)
Principal Investigator: Qin,Yong
Total Amount of Contract, Award, or Gift (Annual before 2011): $ 608,000
Exceeds $250,000 (Is it flagged?): Yes
Start and End Dates: 9/1/22 - 8/31/26
Restricted Research: YES
Academic Discipline: Pharmaceutical Science
Department, Center, School, or Institute: Pharmaceutical Science
Title of Contract, Award, or Gift: SOCS1 as a crucial regulator for uveal melanoma response to immunotherapy
Name of Granting or Contracting Agency/Entity:
NIH - NATIONAL EYE INSTITUTE
CFDA Link: HHS
93.859
Program Title:
Biomedical Research and Research Training
CFDA Linked: Biomedical Research and Research Training
Note:
Uveal melanoma (UM) is among those cancer types that are not responsive to immunotherapies, including checkpoint inhibitors. The mechanism underlying poor response to immunotherapy in UM is unclear. Our initial analysis of UM tumors of patients who received anti-PD-1 immunotherapy showed that suppressor of cytokine signaling 1 (SOCS1) was significantly higher in pre-treatment tumors of responders compared to nonresponders. Moreover, SOCS1 is correlated with patients’ survival based on TCGA data. SOCS1 is a known critical regulator of cytokine signaling and a prominent modulator of the tumor immune microenvironment. To date, a major gap lies in our understanding of the functional role of SOCS1 in UM. Herein, we hypothesize that SOCS1 is a crucial mediator in immune-resistant UM responding to immunotherapy. SOCS1 participates in regulating the expression of MHC molecules in UM, which affects tumor immunogenicity and response to immunotherapies. We propose a series of studies to investigate the role of SOCS1 in immune-silent UM tumors. To our knowledge, this proposed study has not previously been reported nor investigated. This study will generate enormous data and provide insights into SOCS1 signaling in UM, which will lay a solid foundation for discovering biomarkers and developing a new effective therapy for UM.
Discussion: No discussion notes